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ABSTRACT
Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-
versus-host disease (GVHD). In a single-institution phase III trial, 95 recipients of allogeneic peripheral blood
stem cell (PBSC) transplantation were randomized to receive, in a double-blind fashion, and in addition to
prophylactic cyclosporine A (CSA), HCQ, or placebo starting 21 days pretransplant and continued until day
365. HCQ was very well tolerated and not associated with side effects. Overall, the incidence of acute GVHD
(aGVHD) was 59% in both arms, and severe aGVHD occurred in 11% (HCQ) and 14% (placebo) (P  .76).
Sixty percent and 78% of patients developed chronic GVHD (cGVHD) in the HCQ and the placebo arms,
respectively (P  .15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were
comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had
no effects on aGVHD or cGVHD or survival.
© 2007 American Society for Blood and Marrow Transplantation
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dNTRODUCTION
Cytokine-mobilized peripheral blood stem cells
PBSCs) have increasingly replaced bone marrow as
he source of hematopoietic cell support for allogeneic
ransplantation. Indeed, allografting with PBSCs
s associated with faster hematologic engraftment,
horter hospitalization, and improved early immune
econstitution [1-3]. However, and despite modern
harmacologic prophylaxis, chronic graft-versus-host
isease (cGVHD) remains a signiﬁcant limiting factor
or the success of transplantation [4]. Compared to
one marrow, most studies have reported higher in-
idence of cGVHD following allogeneic PBSC trans-
lants, with a relative risk of 2.2 and actuarial risk of
0% at 2 years in some reports [5,6]. lHydroxychloroquine (HCQ) is a lysosomotropic
mine that interferes with major histocompatibility
lass-II dependent antigen processing and presenta-
ion, and reduces T cell proliferation in response to
ultiple stimuli [7-9]. HCQ acts synergistically with
he immunosuppressive activity of cyclosporine A
CSA), and has anti-GVHD activity postallogeneic
ransplants in both murine models and humans [9-14].
e previously reported favorable GVHD outcomes
f unrelated donor transplant recipients who received
rophylactic HCQ in addition to standard GVHD
rophylaxis [14]. Encouraged by these results, we de-
igned and conducted a single-institution randomized
ouble-blind study to determine the GVHD prophy-
actic activity of HCQ in a cohort of allogeneic HLA-
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T. Fong et al.1202atched related donor PBSC transplant recipients.
esults of this trial are report herein.
ATERIALS AND METHODS
atients
Patients with hematologic malignancies undergo-
ng HLA-matched related donor PBSC transplanta-
ion were eligible for this trial [15]. Siblings were
equired to be matched at all HLA -A, -B, and -DR
ites, as determined using PCR sequence-speciﬁc oli-
onucleotide probes (SSOP). Patients were classiﬁed
s “early”-stage disease if in ﬁrst complete remission
CR) or ﬁrst chronic phase, chronic myelogenous leu-
emia (CML), “intermediate/advanced” stage disease
f in CR2, partial remission, diagnosed with second-
ry acute leukemia or in accelerated/blast phase CML.
atients with active retinitis or any ophthalmologic
hysical barrier for a complete fundoscopic exam (i.e.,
ataract) were ineligible for this study. The institu-
ional review board of Washington University School
f Medicine approved the study, and all patients gave
ritten informed consent.
tudy Drug Administration
Patients were randomized to receive, starting 21
ays prior to transplantation and to continue for 365
ays posttransplant, either HCQ (Plaquenil®, kindly
rovided by Sanoﬁ Pharmaceuticals) 400 mg, or pla-
ebo, orally twice daily in a double-blinded fashion.
he study drug was added to the institutional GVHD
rophylaxis regimen consisting of single-agent oral
yclosporine A (CSA), initiated at the dose of 12.5
g/kg/day on day 2 pretransplant. CSA was contin-
ed for 100 days posttransplant, and tapered off sub-
equently in the absence of GVHD. The study drug
as discontinued at any time in cases of relapses of the
nderlying disease.
afety Assessment
Toxicity of HCQ was monitored with visual acuity
nd fundoscopic examination performed prior to the
nitiation of HCQ, on days 30, 100, and yearly
hereafter.
onor Stem Cells Mobilization and Collection
Donors were mobilized with granulocyte colony-
timulating factor (G-CSF, Neupogen®, Amgen,
housand Oaks, CA) (10 g/kg per day) (n  23)
lone, G-CSF (10 g/kg per day) plus granulocyte-
acrophage CSF (GM-CSF, Leukine®, Berlex, Rich-
ond, CA) (5 g/kg per day) (n  58), or GM-CSF
10 g/kg per day) alone (n  13). PBSCs were col-
ected through large volume aphereses beginning 5
ays after initiation of growth factors and continued entil at least 2.0  106 CD 34 cells per kilogram
ctual recipient body weight were collected [15].
onditioning Regimen and Transplantation
Patients were enrolled on a concomitant institu-
ional conditioning regimen trial assessing the effects
f high dose rate/low total dose-single exposure total
ody irradiation (TBI), and received cyclophospha-
ide (60 mg/kg/day i.v. on days 3 and 2), and
ow-dose (550 cGy) TBI delivered as a single dose at
high dose rate (30 cGy/min, 15%) on day 1, as
reviously described [16]. Within 8 hours of TBI,
nmanipulated donor PBSC were infused intrave-
ously.
upportive Care
Patients received prophylactic acyclovir and tri-
ethoprim-sulfamethoxazole according to the Wash-
ngton University Bone Marrow Transplantation in-
titutional policies. All patients were nursed in laminar
irﬂow rooms equipped with high-efﬁcacy particulate
ir ﬁlters for protective isolation. G-CSF, 10 g/kg/
ay subcutaneously, was started on posttransplant day
, and discontinued upon neutrophil engraftment.
iagnosis, Staging, and Treatment of GVHD
Acute GVHD (aGVHD) and cGVHD were diag-
osed clinically and staged according to internation-
lly accepted standard criteria [17,18]. GVHD assess-
ents were performed by the attending physician on a
aily basis on the inpatient ward, weekly in the out-
atient department until day 30, biweekly until day
00, and on a monthly basis thereafter until day365.
GVHD was documented by skin biopsies. Colon and
iver biopsies were obtained in case of unexplained
yperbilirubinemia, or GVHD-suspected diarrhea.
typical clinical presentations of cGVHD were con-
rmed histologically. The initial treatment for aGVHD
onsisted of methylprednisolone (2 mg/kg), and patients
ith steroid-refractory aGVHD or cGVHD were en-
olled on investigational trials.
tatistical Considerations
This phase III trial was designed to detect a 25%
eduction in the incidence of cGVHD in the study
roup compared to the control group. Based on the
istoric institutional prevalence of cGVHD (actuarial
robability 0.87  0.15) [6], a target accrual of 110
atients was estimated to provide 80% power at a .05
igniﬁcance level. Treatments were compared for time
o event (data including development of aGVHD and
GVHD, relapse, relapse-free survival, and overall
urvival [OS]) using the Kaplan-Meier method (log
ank test). One-year rates were compared using Fish-
r’s Exact test. Those who died without cGVHD
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Prophylaxis of GVHD with Hydroxychloroquine 1203efore day 365 were censored at the time of death for
eing cGVHD-free.
ESULTS
atient Characteristics
Between April 1999 and May 2003, 109 patients
ere registered to the study, and 104 were random-
zed. Two patients were subsequently deemed ineligi-
le because they met exclusion criteria, and 7 (3 in
CQ arm, 4 in placebo arm) were inevaluable because
f missing information. Thus, a total of 95 patients
ere evaluable and are included in this analysis: 46 in
he HCQ arm and 49 in the placebo arm. Character-
stics of patients are summarized in Table 1. Patients
ere evenly distributed among the 2 groups with re-
ard to age, diagnoses, disease status at time of trans-
lantation, and sex mismatch between donors and
ecipients. Speciﬁcally, 30% male patients received a
raft from a female donor in the HCQ group, and
0% in the placebo group (P  .35).
oxicity
HCQ was well tolerated, with no cases of retinal
oxicity observed. Only 2 patients (1 in the HCQ arm,
able 1. Patient Characteristics
HCQ
(n  46)
Placebo
(n  49)
ge, median (years), range 48 (20-64) 46 (21-65)
ex (M/F) 31/15 27/22
iagnosis
A L 20 21
CML 7 8
NHL 14 8
MDS 4 5
*Other 1 7
isease stage n (%)
Early 25 (54) 24 (49)
Intermediate/advanced 21 (46) 25 (51)
donor/M recipient n (%) 14 (30) 10 (20)
L indicates acute leukemias; CML, chronic myelogenous leuke-
mia; NHL, non-Hodgkin lymphoma; MDS, myelodysplasia.
Other: chronic lymphocytic leukemia, Hodgkin disease, multiple
myeloma, posttransplant NHL.
able 2. GVHD
aGVHD Glucksberg’s grade I-II
CQ n (%) 22 (48%)
lacebo n (%) 22 (45%)
cGVHD Limited Extensive None
Died or Relapse
Before cGVHD D
CQ 4 17 15 8
lacebo 3 27 9 8GVHD indicates chronic graft-versus-host disease; aGVHD, acute graft-in the placebo arm) experienced mild gastrointesti-
al side effects pretransplant, which were easily man-
ged with intermittent antiemetics and did not require
iscontinuation of the study medication.
VHD
aGVHD (grades I-IV) occurred in 27 patients
59%) in the HCQ arm and 29 patients (59%) in the
lacebo arm (P  .87) (Table 2) and consisted of
tages I-II skin-only involvement in the majority of
ases (64%). Of those patients, 5 (11%) and 7 (14%)
atients experienced severe aGVHD (grades III-IV) in
he HCQ and placebo arms, respectively (P  .76,
isher’s Exact test). The organ systems involved and
he stages or aGVHD were comparable in both
roups and are summarized in Table 2.
The incidence of cGVHD was 0.6 (95% conﬁ-
ence interval [CI]: 0.43-0.76) in the HCQ group and
.78 (95% CI: 0.62-0.89) in the placebo arm (Table
). The median time of onset of cGVHD was 181
162, 334) days in the HCQ arm and 173 (134, 245)
ays in the placebo arm (P .31). Immunosuppressive
rugs, including the study drug, were rapidly tapered
nd discontinued when patients experienced relapsed
isease; therefore, cGVHD was also analyzed after
djusting for relapses, and no differences were ob-
erved between the 2 arms of the study (Figure 1).
GVHD was extensive in the majority of cases (74%
CQ and 84% placebo) (P  .60) with comparable
rgan involvement in the 2 arms of the study. Eighty-
ne percent of patients in the HCQ group and 83% in
he placebo group (P  .99) were still receiving cor-
icosteroids for GVHD on posttransplant day 365.
mmune Reconstitution
The effects of HCQ on lymphocyte subsets were
ssessed independently of the transplant on pretrans-
lant days 21 and 14 and on posttransplant days
0, 100, and 365. The addition of HCQ had no effects
n lymphocyte subsets pre- and posttransplant (data
ot shown). Additionally, HCQ serum IgG levels
easured on day 100 posttransplant were comparable
mong the 2 groups (median IgG 466 mg/dL (range:
III IV Censored
3 (6%) 2 (4%) 19
3 (6%) 4 (8%) 20
Incidence as % of Patients
Alive and Relapse-Free Overall Incidence No cGVHD
23/38 (60%) 23/46 (50%) 23
32/41 (78%) 32/49 (65%) 17d
xversus-host disease.
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T. Fong et al.120426-1080) in the HCQ group and 657 mg/dL (range:
48-3240) in the placebo group; P  .54).
urvival
With a median follow-up of 35 months, no signif-
cant differences in OS were observed for patients in
he HCQ and the placebo arm (Figure 2, P  .56). 21
46%) and 19 (39%) patients had relapsed disease in
CQ and placebo groups, respectively (P .54, Fish-
r’s Exact test). Among patients who relapsed, median
ime to relapse was 151 (range: 26-985) and 139
range: 78-547) days for early-stage patients, 99
igure 1.Cumulative incidence of cGVHD for patients enrolled on
he HCQ prophylactic trial according to the randomization group
nd the presence or not of relapse at the time of cGVHD.
igure 2. Kaplan-Meier overall survival estimate for patients en-
olled on the HCQ prophylactic trial according to the randomiza-Hion group.range: 20-932) and 209 (68-1502) days for interme-
iate/advanced stage, in the HCQ and placebo arms,
espectively (P  .41, log-rank test) (Figure 3).
hirty-four patients (74%) died in the HCQ and 36 in
he placebo arm (74%) (P  .56). Causes of death
ncluded progressive disease in 13 (28%) and 16
33%), infection and/or GVHD in 17 (37%) and 12
24%), and other or undetermined causes in 4 (9%)
nd 8 (16%) patients in the HCQ and placebo arms,
espectively.
ISCUSSION
The purpose of this study was to establish in a
omogeneously treated group of allograft recipients
he GVHD prophylactic effects of HCQ when added
o CSA. Patients with hematologic malignancies en-
olled on this trial received identical conditioning reg-
mens, cytokine-mobilized PBSCs, and consistent
upportive care at a single institution. This patient
opulation was selected based on a historically high
isk for cGVHD [6]. The addition of HCQ to CSA
as very well tolerated and not associated with signif-
cant side effects. Retinal toxicity was not observed in
ny patients. Immune reconstitution was not affected
y the addition of HCQ; speciﬁcally, CD4/CD8
atios were not affected, and infection was not in-
reased in patients receiving HCQ.
In this randomized study, the incidence of
GVHD was identical in the HCQ and placebo arms
59%). The incidence of severe aGVHD was relatively
ow and comparable in both arms (11% and 14%).
GVHD was observed in 60% of patients receiving
igure 3. Kaplan-Meier relapse-free survival estimate for patients
nrolled on the HCQ prophylactic trial according to the random-
zation group. Median follow-up is 409 days.CQ, and 78% in the placebo group. Although a
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Prophylaxis of GVHD with Hydroxychloroquine 1205rend in favor of lower incidence of cGVHD and a
elay in its onset were observed by the addition of
CQ, these differences did not achieve statistical sig-
iﬁcance (P  .15). This incidence of cGVHD was
omparable in both arms independently from relapses
nd subsequent discontinuation of immunosuppres-
ion (Figure 1). Of interest, the incidence of cGVHD
n the placebo group was lower than what has been
reviously reported in our institutional retrospective
nalysis [6], and comparable to incidences observed in
rospective randomized trials [19,20], highlighting
he difﬁculties in grading cGVHD retrospectively.
either the organ system involvement by cGVHD
or the percentage of patients receiving corticoste-
oids for GVHD at 1 year were affected by the addi-
ion of HCQ to CSA.
As GVHD cannot be separated from graft-versus-
umor effects, reducing cGVHD often leads to in-
reases in relapses of the underlying malignancy. In
his trial, the trend for a reduced prevalence of
GVHD was associated with a trend for higher relapse
ates at 1 year among patients receiving HCQ, but did
ot achieve statistical signiﬁcance (37% versus 24%;
 .26, Fisher’s Exact test). Additionally, and when
nalyzed within cohorts of comparable risks for re-
apse (early versus intermediate/advanced disease), no
ifferences in relapse rates were observed in patients
eceiving either HCQ or placebo (Figure 3).
HCQ was initiated 21 days prior to transplanta-
ion based on murine transplant models and a previous
hase II trial. Initiation of HCQ prior to marrow
nfusion, and its continuation posttransplant, resulted
n near complete elimination of aGVHD and a
arked survival advantage in HCQ-treated murine
ecipients of minor histocompatibility antigen mis-
atched transplants [12]. In the phase II trial previ-
usly conducted at our institution, prophylactic HCQ
as initiated 21 days prior to unrelated donor trans-
lantation, and its addition to CSA, methotrexate
MTX), and prednisone was associated with low inci-
ences of grades III-IV aGVHD (16%). Additionally,
better GVHD-free survival was observed in HCQ-
reated recipients when compared to a matched cohort
f unrelated donors reported to the International
one Marrow Transplant Registry [14].
The current study was powered to detect a 25%
eduction in the incidence of cGVHD based on our
istoric incidences of cGVHD (80%). It is therefore
ossible that the number of patients enrolled may
ave been insufﬁcient to adequately detect a true but
maller beneﬁcial effect by the addition of HCQ to
SA. Additionally, and in contrast to the phase II
rophylactic trial where HCQ was added to CSA,
rednisone, and MTX, HCQ was combined with sin-
le-agent CSA in this study. HCQ was administered
or the ﬁrst 365 days posttransplant. Considering the
elayed onset of cGVHD in the HCQ group com-ared to placebo, it is possible, albeit unlikely, that a
ore prolonged administration of HCQ (beyond 365
ays) could have been associated with better cGVHD-
ree survival. Finally, serum HCQ levels were not
btained in this randomized trial, as data from the
hase II trial failed to demonstrate a correlation be-
ween serum levels and GVHD prophylactic effects
14].
In summary, this is the ﬁrst randomized double-
lind study assessing the prophylactic activity of HCQ
fter allogeneic PBSC transplantation. No effects on
GVHD, cGVHD, or survival were observed.
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